S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 AI Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The A.I. story nobody is telling you (Read ASAP) (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Your Money is Not Safe (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 AI Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The A.I. story nobody is telling you (Read ASAP) (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Your Money is Not Safe (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 AI Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The A.I. story nobody is telling you (Read ASAP) (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Your Money is Not Safe (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Top 5 AI Stocks to Buy for 2024 (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
The A.I. story nobody is telling you (Read ASAP) (Ad)
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Your Money is Not Safe (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
Free Trial
ASX:MEM

Memphasys (MEM) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)
Free MEM Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
246,322 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.20%
Price Target
N/A
Stock Analysis
Stock Analysis
MEM stock logo

About Memphasys Stock (ASX:MEM)

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

MEM Stock News Headlines

May 22, 2023 | hk.finance.yahoo.com
Memphasys Reaches AU$20m Market Cap Benefiting Insider Stock Buying
May 20, 2023 | finance.yahoo.com
Memphasys Reaches AU$20m Market Cap Benefiting Insider Stock Buying \
April 18, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
April 5, 2023 | afr.com
Blood pressure rises at Aegros, the next plasma hopeful
April 2, 2023 | msn.com
Dr Boreham’s Crucible: Every sperm is sacred – and profitable
March 9, 2023 | finance.yahoo.com
Memphasys Limited (IG7.F)
February 25, 2023 | finance.yahoo.com
Memphasys First Half 2023 Earnings: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2022)
February 23, 2023 | marketwatch.com
Research Insight View on Centrifugation-free Sperm Separation Systems Market Size [2023-2028] | Emerging Trend and Current Developments
April 18, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
February 6, 2023 | msn.com
ASX Health Stocks: Creso eyes psychedelic spinout off the back of landmark TGA decision
December 11, 2022 | finance.yahoo.com
A Memphasys Limited (ASX:MEM) insider increased their holdings by 6.2% last year
July 27, 2022 | afr.com
Placement outbreak: Creso Pharma, New World, Memphasys chase investors
June 9, 2022 | msn.com
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
March 20, 2022 | proactiveinvestors.com.au
Memphasys achieves quality certification for medical devices and diagnostics
January 26, 2022 | proactiveinvestors.com.au
Memphasys outlines vision for biological separation tech in 2022
December 8, 2021 | msn.com
Standouts: 3 ASX biotech shares that outperformed in November
December 7, 2021 | au.finance.yahoo.com
Memphasys Limited (MEM.AX)
November 16, 2021 | msn.com
These 3 ASX healthcare shares are soaring today. Why?
November 2, 2021 | msn.com
ASX Health Stocks: Paradigm rockets 21pc after getting FDA nod, Memphasys up 31pc on imminent launch
July 29, 2021 | fool.com.au
Ellume is making news and these ASX shares are surging, again
July 28, 2021 | msn.com
When Ellume is making news, these ASX shares are in focus
See More Headlines
Receive MEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Memphasys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:MEM
CUSIP
N/A
CIK
N/A
Web
www.memphasys.com
Phone
61 2 8415 7300
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,520,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.98%
Return on Assets
-16.93%

Debt

Debt-to-Equity Ratio
83.82
Current Ratio
0.17
Quick Ratio
0.39

Sales & Book Value

Annual Sales
$81,148.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
12.20
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,370,000,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.72
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. David Ali
    Acting CEO & Executive Director
  • Pablo Neyertz
    Director of Finance
  • Associate Prof. Hassan Bakos
    Director of Operations
  • Prof. R. John Aitken Ph.D.
    ScD FRSE, Scientific Director
  • Mr. Andrew Metcalfe B.Bus
    CPA, FGIA, MAICD, Company Secretary

Key Competitors

View All Competitors

This page (ASX:MEM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Urgent alert: open this for a huge profit potential
Timothy Sykes
Your Money is Not Safe
American Alternative